Peter B Berger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11922274/publications.pdf

Version: 2024-02-01

234 papers	30,963 citations	7096 78 h-index	4342 173 g-index
240 all docs	240 docs citations	240 times ranked	16066 citing authors

#	Article	IF	Citations
1	Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2002, 288, 2411.	7.4	2,791
2	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. New England Journal of Medicine, 2006, 354, 1706-1717.	27.0	2,582
3	Incidence and Prognostic Importance of Acute Renal Failure After Percutaneous Coronary Intervention. Circulation, 2002, 105, 2259-2264.	1.6	1,540
4	Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2011, 305, 1097.	7.4	1,185
5	ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgeryâ€"executive summary. Journal of the American College of Cardiology, 2002, 39, 542-553.	2.8	908
6	The Perioperative Management of Antithrombotic Therapy. Chest, 2008, 133, 299S-339S.	0.8	763
7	Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. Journal of the American College of Cardiology, 2007, 49, 1982-1988.	2.8	752
8	Variability in platelet responsiveness to clopidogrel among 544 individuals. Journal of the American College of Cardiology, 2005, 45, 246-251.	2.8	713
9	Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment<SUBTITLE>The ISAR-REACT 2 Randomized Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2006, 295, 1531.	7.4	682
10	The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. Journal of the American College of Cardiology, 2002, 39, 1113-1119.	2.8	671
11	Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease. New England Journal of Medicine, 2005, 353, 46-57.	27.0	636
12	ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgeryâ€"Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 292	1.6	582
13	A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel. New England Journal of Medicine, 2004, 350, 232-238.	27.0	557
14	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, The, 2013, 382, 1714-1722.	13.7	537
15	Relationship Between Delay in Performing Direct Coronary Angioplasty and Early Clinical Outcome in Patients With Acute Myocardial Infarction. Circulation, 1999, 100, 14-20.	1.6	532
16	Utilization of Early Invasive Management Strategies for High-Risk Patients With Nonâ€"ST-Segment Elevation Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2004, 292, 2096.	7.4	525
17	Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions. Journal of the American College of Cardiology, 2008, 51, 690-697.	2.8	452
18	Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. Journal of the American College of Cardiology, 2003, 42, 234-240.	2.8	437

#	Article	IF	Citations
19	Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention. Circulation, 2011, 124, 1132-1137.	1.6	381
20	Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience. Journal of the American College of Cardiology, 1995, 26, 668-674.	2.8	368
21	Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention. Circulation, 2001, 103, 2572-2578.	1.6	361
22	Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention. New England Journal of Medicine, 2008, 359, 688-696.	27.0	323
23	Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. Journal of the American College of Cardiology, 2002, 39, 9-14.	2.8	313
24	Implementation of a Statewide System for Coronary Reperfusion for ST-Segment Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2007, 298, 2371.	7.4	309
25	Analysis of Risk of Bleeding Complications After Different Doses of Aspirin in 192,036 Patients Enrolled in 31 Randomized Controlled Trials. American Journal of Cardiology, 2005, 95, 1218-1222.	1.6	304
26	Abciximab and Heparin versus Bivalirudin for Nonâ€“ST-Elevation Myocardial Infarction. New England Journal of Medicine, 2011, 365, 1980-1989.	27.0	285
27	Lack of Adverse Clopidogrelâ€“Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial. Circulation, 2003, 108, 921-924.	1.6	259
28	The Primary and Secondary Prevention of Coronary Artery Disease. Chest, 2008, 133, 776S-814S.	0.8	234
29	ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery---executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	234
30	Cardiogenic Shock in Patients With Acute Ischemic Syndromes With and Without ST-Segment Elevation. Circulation, 1999, 100, 2067-2073.	1.6	225
31	Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease. Circulation, 2010, 121, 2575-2583.	1.6	218
32	Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. European Heart Journal, 2005, 26, 137-144.	2.2	215
33	Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. Journal of Lipid Research, 2007, 48, 425-433.	4.2	215
34	Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women. Circulation, 2005, 111, 940-953.	1.6	214
35	Perioperative Management of Patients With Coronary Stents. Journal of the American College of Cardiology, 2007, 49, 2145-2150.	2.8	188
36	Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. Thrombosis and Haemostasis, 2011, 106, 571-584.	3.4	188

#	Article	IF	Citations
37	Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. American Heart Journal, 2004, 147, 463-467.	2.7	178
38	Optimal Timing for the Initiation of Pre-Treatment With 300 mg Clopidogrel Before Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2006, 47, 939-943.	2.8	177
39	Impact of an Aggressive Invasive Catheterization and Revascularization Strategy on Mortality in Patients With Cardiogenic Shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) Trial. Circulation, 1997, 96, 122-127.	1.6	177
40	The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. American Heart Journal, 2008, 155, 687-693.	2.7	175
41	Long-Term Clinical Outcome in the Bypass Angioplasty Revascularization Investigation Registry. Circulation, 2000, 101, 2795-2802.	1.6	173
42	A Multicenter, Randomized Trial of Coronary Angioplasty Versus Directional Atherectomy for Patients With Saphenous Vein Bypass Graft Lesions. Circulation, 1995, 91, 1966-1974.	1.6	169
43	Cardiogenic shock complicating acute coronary syndromes. Lancet, The, 2000, 356, 749-756.	13.7	168
44	Clopidogrel versus ticlopidine after intracoronary stent placement. Journal of the American College of Cardiology, 1999, 34, 1891-1894.	2.8	161
45	Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. Journal of the American College of Cardiology, 2004, 44, 2133-2136.	2.8	156
46	Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding. Annals of Internal Medicine, 2009, 150, 379.	3.9	152
47	Plasma Ceramides. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1933-1939.	2.4	147
48	Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel. Archives of Internal Medicine, 2004, 164, 2051.	3.8	142
49	Frequency of Major Noncardiac Surgery and Subsequent Adverse Events in the Year After Drug-Eluting Stent Placement. JACC: Cardiovascular Interventions, 2010, 3, 920-927.	2.9	141
50	Frequency and correlates of coronary stent thrombosis in the modern era. Journal of the American College of Cardiology, 2002, 40, 1567-1572.	2.8	135
51	Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease. Circulation, 2009, 120, 2337-2344.	1.6	123
52	The Relative Efficacy and Safety of Clopidogrel in Women and Men. Journal of the American College of Cardiology, 2009, 54, 1935-1945.	2.8	119
53	Validity of International Classification of Disease Codes to Identify Ischemic Stroke and Intracranial Hemorrhage Among Individuals With Associated Diagnosis of Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 8-14.	2.2	116
54	Influence of coronary thrombus on outcome of percutaneous coronary angioplasty in the current era (the Mayo Clinic experience). American Journal of Cardiology, 2001, 88, 1091-1096.	1.6	111

#	Article	IF	Citations
55	Triple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survival. Journal of the American College of Cardiology, 2003, 42, 1188-1195.	2.8	111
56	Long-Term Outcome and its Predictors Among Patients With ST-Segment Elevation Myocardial Infarction Complicated by Shock. Journal of the American College of Cardiology, 2007, 50, 1752-1758.	2.8	110
57	Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial. American Heart Journal, 2009, 157, 818-824.e1.	2.7	110
58	Systems of Care for ST-Segmentâ€“Elevation Myocardial Infarction: A Report From the American Heart Associationâ€™s Mission: Lifeline. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 423-428.	2.2	110
59	Pro-Inflammatory Interleukin-1 Genotypes Potentiate the Risk of Coronary Artery Disease and Cardiovascular Events Mediated by Oxidized Phospholipids and Lipoprotein(a). Journal of the American College of Cardiology, 2014, 63, 1724-1734.	2.8	110
60	Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. Journal of the American College of Cardiology, 2000, 36, 2168-2173.	2.8	109
61	Clinical Outcomes of Patients With Diabetic Nephropathy Randomized to Clopidogrel Plus Aspirin Versus Aspirin Alone (A post hoc Analysis of the Clopidogrel for High Atherothrombotic Risk and) Tj ETQq1 1 0.784314 rgBT /Overlock 1 2009, 103, 1359-1363.	1.6	107
62	Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: Results from TIMI II. Journal of the American College of Cardiology, 1992, 20, 533-540.	2.8	106
63	Frequency and significance of right ventricular dysfunction during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy (results from the Thrombolysis in) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	3.6	105
64	Safety and Efficacy of Ticlopidine for Only 2 Weeks After Successful Intracoronary Stent Placement. Circulation, 1999, 99, 248-253.	1.6	103
65	Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. American Heart Journal, 2007, 154, 3-11.	2.7	103
66	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting. Circulation: Cardiovascular Interventions, 2011, 4, 522-534.	3.9	103
67	Impact of Regionalization of ST-Segmentâ€“Elevation Myocardial Infarction Care on Treatment Times and Outcomes for Emergency Medical Servicesâ€“Transported Patients Presenting to Hospitals With Percutaneous Coronary Intervention. Circulation, 2018, 137, 376-387.	1.6	101
68	Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. American Heart Journal, 2004, 147, 815-822.	2.7	100
69	Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet, The, 1997, 349, 75-78.	13.7	95
70	One-Year Survival Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock, and its Relation to Early Revascularization. Circulation, 1999, 99, 873-878.	1.6	91
71	Door-to-Balloon Times Under 90 Min Can Be Routinely Achieved for Patients Transferred for ST-Segment Elevation Myocardial Infarction Percutaneous Coronary Intervention in a Rural Setting. Journal of the American College of Cardiology, 2011, 57, 272-279.	2.8	88
72	Incidence and Prognostic Significance of Thrombocytopenia in Patients Treated With Prolonged Heparin Therapy. Archives of Internal Medicine, 2008, 168, 94.	3.8	87

#	Article	IF	Citations
73	Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. American Journal of Cardiology, 1999, 83, 1006-1011.	1.6	86
74	Outcome of Patients Undergoing Balloon Angioplasty in the Two Months Prior to Noncardiac Surgery. American Journal of Cardiology, 2005, 96, 512-514.	1.6	86
75	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. European Heart Journal, 2012, 33, 2143-2150.	2.2	86
76	Clinical safety of magnetic resonanceimaging early after coronary artery stent placement. Journal of the American College of Cardiology, 2003, 42, 1295-1298.	2.8	82
77	Referral for coronary artery revascularization procedures after diagnostic coronary angiography: Evidence for gender bias?. Journal of the American College of Cardiology, 1995, 25, 1650-1655.	2.8	81
78	Intercenter variability in outcome for patients treated with direct coronary angioplasty during acute myocardial infarction. American Heart Journal, 1998, 135, 310-317.	2.7	81
79	Regional Systems of Care Demonstration Project. Circulation, 2016, 134, 365-374.	1.6	81
80	Management of Patients Undergoing Percutaneous Coronary Revascularization. Annals of Internal Medicine, 2003, 139, 123.	3.9	79
81	Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. Journal of the American College of Cardiology, 2001, 38, 1440-1449.	2.8	75
82	Frequency of Early Occlusion and Stenosis in a Left Internal Mammary Artery to Left Anterior Descending Artery Bypass Graft After Surgery Through a Median Sternotomy on Conventional Bypass. Circulation, 1999, 100, 2353-2358.	1.6	72
83	Effect of age on the outcome of angioplasty for acute myocardial infarction among patients treated at the Mayo Clinic. American Journal of Medicine, 2000, 108, 187-192.	1.5	72
84	Long-term Outcome of Women Compared With Men After Successful Coronary Angioplasty. Circulation, 1995, 91, 2876-2881.	1.6	72
85	Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal, 2009, 157, 369-374.	2.7	69
86	Cardiovascular disease and chronic kidney disease: Insights and an update. American Heart Journal, 2004, 148, 230-242.	2.7	66
87	Predictors of improvement in left ventricular function after percutaneous revascularization of occluded coronary arteries: A report from the Total Occlusion Study of Canada (TOSCA). American Heart Journal, 2001, 142, 301-308.	2.7	65
88	Prevalence and Prognostic Significance of Preprocedural Cardiac Troponin Elevation Among Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Circulation, 2008, 118, 632-638.	1.6	64
89	Impact of mild or moderate chronic kidney disease on the frequency of restenosisResults from the PRESTO trial. Journal of the American College of Cardiology, 2004, 44, 1786-1791.	2.8	63
90	Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis. Journal of the American College of Cardiology, 1996, 28, 361-367.	2.8	62

#	Article	IF	Citations
91	Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrology Dialysis Transplantation, 2005, 20, 2105-2112.	0.7	62
92	Balloon angioplasty of chronic total coronary artery occlusions: What does it cost in radiation exposure, time, and materials?. Catheterization and Cardiovascular Diagnosis, 1992, 25, 10-15.	0.3	61
93	Outcome â‰¥10 Years After Successful Percutaneous Transluminal Coronary Angioplasty. American Journal of Cardiology, 1997, 79, 1005-1011.	1.6	59
94	An immediate invasive strategy for the treatment of acute myocardial infarction early after noncardiac surgery. American Journal of Cardiology, 2001, 87, 1100-1102.	1.6	59
95	Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Journal of the American College of Cardiology, 1996, 27, 1-7.	2.8	57
96	Application of the New York State PTCA Mortality Model in Patients Undergoing Stent Implantation. Circulation, 2000, 102, 517-522.	1.6	57
97	Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. European Heart Journal, 2010, 31, 582-587.	2.2	57
98	Coronary Artery Bypass Graft Surgery Versus Drug-Eluting Stents for Patients With Isolated Proximal Left Anterior Descending Disease. Journal of the American College of Cardiology, 2014, 64, 2717-2726.	2.8	56
99	One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. European Heart Journal, 2008, 29, 455-461.	2.2	55
100	Readmission in the 30 Days After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2013, 6, 237-244.	2.9	55
101	Evaluation of long-term survival after successful percutaneous coronary intervention among patients with chronic renal failureâˆ—âˆ—The content of this manuscript is not associated with any financial interest or other relations that could lead to a conflict of interest.. American Journal of Cardiology, 2001, 87, 630-633.	1.6	54
102	Acute myocardial infarction complicated by heart block in the elderly: Prevalence and outcomes. American Heart Journal, 2001, 141, 47-54.	2.7	53
103	Prognostic Value of Access and Nonâ€“Access Sites Bleeding After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2013, 6, 354-361.	3.9	53
104	Pre-treatment with P2Y₁₂inhibitors in ACS patients: who, when, why, and which agent?. European Heart Journal, 2016, 37, 1284-1295.	2.2	52
105	Primary percutaneous coronary interventions in patients with acute myocardial infarction and prior coronary artery bypass grafting. American Heart Journal, 2001, 142, 452-459.	2.7	51
106	Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. European Heart Journal, 2008, 30, 290-296.	2.2	51
107	Patients With Chronic Total Occlusions Undergoing Percutaneous Coronary Interventions. Circulation: Cardiovascular Interventions, 2016, 9, e003586.	3.9	49
108	In-hospital and long-term outcomes of multivessel percutaneous coronary revascularization after acute myocardial infarction. American Journal of Cardiology, 2005, 95, 349-354.	1.6	48

#	Article	IF	Citations
109	The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: The Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal, 2005, 149, 869-875.	2.7	48
110	Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. American Heart Journal, 2003, 146, 345-350.	2.7	47
111	Methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms: association with serum homocysteine and angiographic coronary artery disease in the era of flour products fortified with folic acid. Atherosclerosis, 2003, 168, 315-322.	0.8	46
112	Clinical Implications of Percutaneous Coronary Intervention-Clopidogrel in Unstable angina to prevent Recurrent Events (PCI-CURE) Study. Circulation, 2002, 106, 2284-2287.	1.6	45
113	Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. American Heart Journal, 2009, 157, 651-657.	2.7	45
114	Predictors of Reperfusion Delay in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention from the HORIZONS-AMI Trial. American Journal of Cardiology, 2010, 106, 1527-1533.	1.6	45
115	Treatment of Saphenous Vein Bypass Grafts With Ultrasound Thrombolysis. Circulation, 2003, 107, 2331-2336.	1.6	44
116	One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrelâ€. European Heart Journal, 2005, 26, 1379-1384.	2.2	44
117	Impact of Proton Pump Inhibitor Therapy on the Efficacy of Clopidogrel in the CAPRIE and CREDO Trials. Journal of the American Heart Association, 2013, 2, e004564.	3.7	44
118	Association of Rapid Care Process Implementation on Reperfusion Times Across Multiple ST-Segmentâ€“Elevation Myocardial Infarction Networks. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	44
119	Time to reperfusion with direct coronary angioplasty and thrombolytic therapy in acute myocardial infarction. American Journal of Cardiology, 1994, 73, 231-236.	1.6	43
120	Temporal Trends in the Use of Early Cardiac Catheterization in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndromes (Results from CRUSADE). American Journal of Cardiology, 2006, 98, 1172-1176.	1.6	43
121	Optimal P2Y 12 Inhibitor in Patients WithÂST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1036-1046.	2.9	42
122	Delays in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients Presenting With Cardiogenic Shock. JACC: Cardiovascular Interventions, 2018, 11, 1824-1833.	2.9	42
123	Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal, 2011, 162, 98-105.e1.	2.7	41
124	Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization. American Heart Journal, 2004, 147, 1066-1070.	2.7	40
125	Results of directional atherectomy of primary atheromatous and restenosis lesions in coronary arteries and saphenous vein grafts. American Journal of Cardiology, 1992, 70, 449-454.	1.6	39
126	Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: Results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. American Heart Journal, 2002, 143, 841-846.	2.7	39

#	Article	IF	Citations
127	A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial. Journal of the American College of Cardiology, 2001, 38, E1608-E1613.	2.8	38
128	Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. EuroIntervention, 2015, 11, 196-203.	3.2	38
129	Cardiogenic shockâ€"Beyond the large infarction*. Critical Care Medicine, 2006, 34, 2234-2235.	0.9	36
130	Allergic Reactions to Clopidogrel and Cross-Reactivity to Other Agents. Current Allergy and Asthma Reports, 2011, 11, 52-57.	5.3	36
131	Rationale for on-site cardiac surgery for primary angioplasty: a time for reappraisal. Journal of the American College of Cardiology, 2002, 39, 1881-1889.	2.8	35
132	Paramedic transtelephonic communication to cardiologist of clinical and electrocardiographic assessment for rapid reperfusion of ST-elevation myocardial infarction. Journal of Electrocardiology, 2007, 40, 265-270.	0.9	35
133	Frequency of Allergic or Hematologic Adverse Reactions to Ticlopidine Among Patients With Allergic or Hematologic Adverse Reactions to Clopidogrel. Circulation: Cardiovascular Interventions, 2009, 2, 348-351.	3.9	35
134	Changes in Percutaneous Coronary Interventions Deemed â€œInappropriateâ€•byÂAppropriate Use Criteria. Journal of the American College of Cardiology, 2017, 69, 1234-1242.	2.8	34
135	Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd) Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	33
136	Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. American Journal of Cardiology, 2004, 94, 623-625.	1.6	33
137	Identification, Diagnosis and Treatment of Heparin-induced Thrombocytopenia and Thrombosis: A Registry of Prolonged Heparin Use and Thrombocytopenia among Hospitalized Patients with and without Cardiovascular Disease. Journal of Thrombosis and Thrombolysis, 2005, 19, 11-19.	2.1	33
138	Age-Dependent Effect of Abciximab in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Interventions. Circulation, 2006, 114, 2040-2046.	1.6	33
139	Impact of mild or moderate chronic kidney disease on the frequency of restenosis. Journal of the American College of Cardiology, 2004, 44, 1786-1791.	2.8	32
140	Troponisms, Necrosettes, Enzyme Leaks, Creatinine Phosphokinase Bumps, and Infarctlets. Circulation, 2001, 104, 627-629.	1.6	31
141	Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel?. Circulation: Cardiovascular Interventions, 2012, 5, 77-81.	3.9	30
142	A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal, 2005, 150, 401.e1-401.e7.	2.7	29
143	Long-Term Versus Short-Term Clopidogrel Therapy in Patients Undergoing Coronary Stenting (from) Tj ETQq1 1 0.784314 rgBT /Overl 349-352.	1.6	29
144	Clinical Outcome of Patients Undergoing Endoluminal Coronary Artery Reconstruction With Three or More Stents. Journal of the American College of Cardiology, 1997, 30, 676-681.	2.8	27

#	Article	IF	Citations
145	Relationship Between Baseline Inflammatory Markers, Antiplatelet Therapy, and Adverse Cardiac Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2009, 2, 503-512.	3.9	27
146	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Stroke in Patients with a History of Atrial Fibrillation: Subgroup Analysis of the CHARISMA Randomized Trial. Cerebrovascular Diseases, 2008, 25, 344-347.	1.7	26
147	Comparison of Intermediate-Term Outcomes of Coronary Artery Bypass Grafting Versus Drug-Eluting Stents for Patients â‰¥75ÂYears of Age. American Journal of Cardiology, 2014, 113, 803-808.	1.6	26
148	Association of Coronary Vessel Characteristics With Outcome in Patients With Percutaneous Coronary Interventions With Incomplete Revascularization. JAMA Cardiology, 2018, 3, 123.	6.1	26
149	Improving outcome over time of percutaneous coronary interventions in unstable angina. Journal of the American College of Cardiology, 2000, 36, 674-678.	2.8	25
150	Bleeding After Percutaneous Coronary Intervention With Bivalirudin or Unfractionated Heparin and One-Year Mortality. American Journal of Cardiology, 2010, 105, 163-167.	1.6	25
151	Safety of coronary angiography and percutaneous coronary intervention via the radial versus femoral route in patients on uninterrupted oral anticoagulation with warfarin. American Heart Journal, 2014, 168, 537-544.	2.7	25
152	Influence of Procedural Success on Immediate and Long-Term Clinical Outcome of Patients Undergoing Percutaneous Revascularization of Occluded Coronary Artery Bypass Vein Grafts. Journal of the American College of Cardiology, 1996, 28, 1732-1737.	2.8	23
153	Clopidogrel instead of ticlopidine after coronary stent placement: Is the switch justified?. American Heart Journal, 2000, 140, 354-358.	2.7	23
154	Time to reperfusion and other procedural characteristics of emergency coronary artery bypass surgery after unsuccessful coronary angioplasty. American Journal of Cardiology, 1995, 76, 565-569.	1.6	22
155	Effectiveness and safety of abciximab after failed thrombolytic therapy. American Journal of Cardiology, 2001, 87, 439-442.	1.6	22
156	The Thienopyridines. Journal of Interventional Cardiology, 2002, 15, 85-93.	1.2	21
157	Percutaneous Coronary Intervention for ST-Segment and Non-ST-Segment Elevation Myocardial Infarction at Hospitals With and Without On-site Cardiac Surgical Capability. Mayo Clinic Proceedings, 2004, 79, 738-744.	3.0	21
158	Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: Results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. American Heart Journal, 2007, 154, 158.e1-158.e7.	2.7	21
159	Does Preoperative Platelet Function Predict Bleeding in Patients Undergoing Off Pump Coronary Artery Bypass Surgery?. Journal of Interventional Cardiology, 2015, 28, 223-232.	1.2	21
160	Impact of preâ€hospital electrocardiograms on time to treatment and one year outcome in a rural regional <scp>ST</scp>â€segment elevation myocardial infarction network. Catheterization and Cardiovascular Interventions, 2017, 89, 245-251.	1.7	21
161	Interventional cardiology and intracoronary stentsâ€”a changing practice: Approved vs. nonapproved indications. , 1997, 40, 133-138.		20
162	Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: Results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry. American Heart Journal, 2011, 161, 360-366.	2.7	20

#	Article	IF	Citations
163	Hemorrhagic and Vascular Complications After Percutaneous Coronary Intervention With Adjunctive Abciximab. Mayo Clinic Proceedings, 2001, 76, 890-896.	3.0	19
164	Choosing Between Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting for Patients With Multivessel Disease. Circulation, 2004, 109, 1079-1081.	1.6	18
165	Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. Catheterization and Cardiovascular Interventions, 2017, 89, 190-198.	1.7	18
166	Impact of Regional Systems of Care on Disparities in Care Among Female and Black Patients Presenting With STâ€Šegmentâ€“Elevation Myocardial Infarction. Journal of the American Heart Association, 2017, 6, .	3.7	18
167	Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillation. International Journal of Cardiology, 2017, 227, 808-812.	1.7	18
168	Lack of association between plasma homocysteine and angiographic coronary artery disease in the era of fortification of cereal grain flour with folic acid. Atherosclerosis, 2002, 165, 375-381.	0.8	17
169	Relationship Between Age-Related Macular Degeneration-Associated Variants of Complement Factor H and LOC387715 With Coronary Artery Disease. Mayo Clinic Proceedings, 2007, 82, 301-307.	3.0	17
170	Should bare metal or drugâ€eluting stents be used during PCI of saphenous vein graft lesions: Waiting for Godot?. Catheterization and Cardiovascular Interventions, 2008, 72, 815-818.	1.7	17
171	Optimal Duration of Clopidogrel Use after Implantation of Drug-Eluting Stents â€" Still in Doubt. New England Journal of Medicine, 2010, 362, 1441-1443.	27.0	17
172	Percutaneous Revascularization of Occluded Vein Grafts. Circulation, 1999, 99, 8-11.	1.6	16
173	Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?. , 2000, 1, 83.		16
174	Newer Pharmacotherapy in Patients Undergoing Percutaneous Coronary Interventions: A Guide for Pharmacists and Other Health Care Professionals. Pharmacotherapy, 2006, 26, 1537-1556.	2.6	16
175	Frequency of Coronary Angiography and Revascularization among Men and Women with Myocardial Infarction and Their Relationship to Mortality at One Year: An Analysis of the Geisinger Myocardial Infarction Cohort. Journal of Interventional Cardiology, 2013, 26, 14-21.	1.2	16
176	Utilization of Radial Artery Access for Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction in New York. JACC: Cardiovascular Interventions, 2014, 7, 276-283.	2.9	16
177	Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice. Circulation: Cardiovascular Interventions, 2015, 8, e001712.	3.9	16
178	The risk of drug-eluting stent thrombosis with noncardiac surgery. Current Cardiology Reports, 2007, 9, 406-411.	2.9	15
179	Outcomes After Implantation of the TAXUS Paclitaxel-Eluting Stent in Saphenous Vein Graft Lesions. JACC: Cardiovascular Interventions, 2010, 3, 742-750.	2.9	14
180	Paroxysmal atrial fibrillation and the hazards of under-treatment. International Journal of Cardiology, 2016, 202, 214-220.	1.7	14

#	Article	IF	Citations
181	The Effect of Antiplatelet and Anticoagulant Therapy on the Clinical Outcome of Patients Undergoing Ureteroscopy. Urology, 2013, 82, 773-779.	1.0	13
182	Management of balloon rupture during rigid stent deployment. Catheterization and Cardiovascular Diagnosis, 1995, 35, 211-215.	0.3	12
183	Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. Clinical Research in Cardiology, 2008, 97, 160-168.	3.3	12
184	The thienopyridines in coronary artery disease. Current Cardiology Reports, 1999, 1, 192-198.	2.9	11
185	Hemorrhagic and Vascular Complications After Percutaneous Coronary Intervention With Adjunctive Abciximab. Mayo Clinic Proceedings, 2001, 76, 890-896.	3.0	11
186	Relationship Between Age-Related Macular Degeneration-Associated Variants of Complement Factor H and LOC387715 With Coronary Artery Disease. Mayo Clinic Proceedings, 2007, 82, 301-307.	3.0	11
187	Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. Journal of Thrombosis and Thrombolysis, 2008, 26, 8-13.	2.1	11
188	Noninvasive prediction of residual blood flow within the risk area during acute myocardial infarction: A multicenter validation study of patients undergoing direct coronary angioplasty. American Heart Journal, 1997, 134, 639-646.	2.7	10
189	Bleeding Is Badâ€¦ Isnâ€™t It?. Circulation, 2007, 116, 2776-2778.	1.6	10
190	Is the heat on HEAT-PPCI appropriate?. Lancet, The, 2014, 384, 1824-1826.	13.7	10
191	Antiplatelet Strategies: Evaluating Their Current Role in the Setting of Acute Coronary Syndromes. Clinical Cardiology, 2008, 31, I2-I9.	1.8	9
192	Six-Month Follow-Up of Patients With In-Hospital Thrombocytopenia During Heparin-Based Anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH]) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 29	1.6	9
193	The Glycoprotein IIb/IIIa Inhibitor Wars. Journal of the American College of Cardiology, 2010, 56, 476-478.	2.8	9
194	Use of excimer laser in the treatment of chronic total occlusion of a coronary artery that cannot be crossed with a balloon catheter. Catheterization and Cardiovascular Diagnosis, 1993, 28, 44-46.	0.3	8
195	Should Proton Pump Inhibitors Be Withheld From Patients Taking Clopidogrel?. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 6-7.	2.2	8
196	Incomplete revascularization for percutaneous coronary interventions: Variation among operators, and association with operator and hospital characteristics. American Heart Journal, 2017, 186, 118-126.	2.7	8
197	Feasibility and safety of ad hoc percutaneous coronary intervention in the modern era. Journal of Invasive Cardiology, 2009, 21, 194-200.	0.4	8
198	Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study. American Heart Journal, 2005, 150, 796-799.	2.7	7

#	Article	IF	Citations
199	Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches. Clinical Cardiology, 2008, 31, I21-I27.	1.8	7
200	Sex differences in the treatment and outcomes of patients hospitalized with STâ€elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2020, 95, 196-204.	1.7	7
201	Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA). American Heart Journal, 2001, 142, 776-781.	2.7	6
202	Therapeutic goals for effective platelet inhibition: a consensus document. Reviews in Cardiovascular Medicine, 2006, 7, 214-25.	1.4	6
203	Effects of tissue plasminogen activator therapy on the frequency of acute right ventricular myocardial infarction associated with acute left ventricular infarction. International Journal of Cardiology, 1993, 38, 151-158.	1.7	5
204	ST-elevation myocardial infarction patients can be enrolled in randomized trials before emergent coronary intervention without sacrificing door-to-balloon time. American Heart Journal, 2009, 158, 400-407.	2.7	5
205	Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. American Heart Journal, 2015, 170, 706-714.	2.7	5
206	Immediate and one-year outcome of intracoronary stent implantation in small coronary arteries with 2.5-mm stents. American Heart Journal, 2000, 140, 898-905.	2.7	4
207	Intracoronary Glycoprotein IIb/IIIa Inhibitors. JACC: Cardiovascular Interventions, 2010, 3, 935-936.	2.9	4
208	Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. Clinical Research in Cardiology, 2011, 100, 579-585.	3.3	4
209	Collagen Plug Vascular Closure Devices and Reduced Risk of Bleeding with Bivalirudin Versus Heparin Plus Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Non <scp>ST</scp>â€<scp>S</scp>egment Elevation Myocardial Infarction. Journal of Interventional Cardiology, 2013, 26, 623-629.	1.2	4
210	Resistance to antiplatelet drugs: Is it real or relevant?. Catheterization and Cardiovascular Interventions, 2004, 62, 43-45.	1.7	3
211	Appending Limited Clinical Data to an Administrative Database for Acute Myocardial Infarction Patients. Medical Care, 2016, 54, 538-545.	2.4	3
212	Response to a DifferingÂPerspective. JACC: Cardiovascular Interventions, 2016, 9, 513-515.	2.9	3
213	Impact on stent size and indication for stent placement on immediate outcome. , 1996, 38, 145-151.		2
214	Does Clopidogrel Increase the Degree of Platelet Inhibition When a Platelet Glycoprotein IIb/IIIa Inhibitor Has Been Given? Insights From an Optical Platelet Aggregometry Study. Journal of Thrombosis and Thrombolysis, 2004, 18, 25-30.	2.1	2
215	Can percutaneous coronary interventions reduce death and myocardial infarction in stable and unstable coronary disease?. Catheterization and Cardiovascular Interventions, 2004, 61, 528-536.	1.7	2
216	Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. Clinical Cardiology, 2008, 31, I28-I35.	1.8	2

#	Article	IF	Citations
217	Cyclosporine for Reperfusion Injury After Cardiac Arrest. JAMA Cardiology, 2016, 1, 566.	6.1	2
218	Treatment of Coronary Artery Disease and Acute Myocardial Infarction in Hospitals With and Without On-Site Coronary Artery Bypass Graft Surgery. Circulation: Cardiovascular Interventions, 2019, 12, e007097.	3.9	2
219	Modulating Thrombotic Potential in Catheter-Based Percutaneous Coronary and Peripheral Vascular Interventions. Journal of Thrombosis and Thrombolysis, 2004, 17, 11-20.	2.1	1
220	Routine Platelet Testing Should Not Be Performed on All Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2010, 3, 284-288.	3.9	1
221	P2Y12 Antagonists in Acute Coronary Syndrome: In Whom Should They Be Started, and When?. Current Cardiology Reports, 2011, 13, 320-326.	2.9	1
222	Response to Letters Regarding Article, â€œPlatelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trialâ€• Circulation, 2012, 125, .	1.6	1
223	Finding the Proper Context for the MATRIX Trial. New England Journal of Medicine, 2015, 373, 1069-1070.	27.0	1
224	Allergic Reactions to Clopidogrel and Cross-Reactivity to Other Agents. , 2011, 11, 52.		1
225	Treatment of Acute Myocardial Infarction by Primary Coronary Angioplasty or Intravenous Thrombolysis. Circulation, 2000, 101, E211-2.	1.6	0
226	Enoxaparin may reduce the risk of myocardial infarction among people at increased risk of stent thrombosis, but is unnecessary for most people. Evidence-based Cardiovascular Medicine, 2002, 6, 137-138.	0.0	0
227	Transport and centralization of acute coronary syndrome care. Current Cardiology Reports, 2004, 6, 292-299.	2.9	0
228	Pharmacology of Intravenous Glycoprotein IIb/IIIa Antagonists. , 0, , 95-110.		0
229	Response to Letter Regarding Article, â€œSmoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Diseaseâ€• Circulation, 2010, 122, .	1.6	0
230	A radial resolution to a warfarin worry. Catheterization and Cardiovascular Interventions, 2015, 85, 89-90.	1.7	0
231	Reply. Journal of the American College of Cardiology, 2015, 65, 1716.	2.8	0
232	Review: Early statin therapy does not reduce the composite endpoint of death, MI, or stroke in acute coronary syndromes. ACP Journal Club, 2006, 145, 61.	0.1	0
233	Abstract 17432: Specific Care Process Implementation Associated With Improved Reperfusion Times Across Multiple STEMI Networks: Insights From The AHA Mission: Lifeline STEMI Accelerator Program. Circulation, 2015, 132, .	1.6	0
234	Relation of Operator Volume and Access Site to Short-Term Mortality in Radial Versus Femoral Access for Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2022, , .	1.6	0